About CPS Mexico
This site is the largest overseas manufacturing site of Dr. Reddy’s and is situated in Cuernavaca, 75 km south of Mexico City.
Background
|
Dr. Reddy’s Laboratories Ltd. acquires this facility from Roche Holding. |
|
Roche Holding acquires Syntex |
|
Sales to third parties begin |
|
Manufacture of Naproxen starts (5 tons) |
|
Relocation of chemical plant to Cuernavaca. Still devoted to production of steroids |
|
Syntex is born in Mexico City as bulk manufacturer of steroids |
Syntex, prior to its takeover by Roche in 1994 was a major pharmaceutical company that has to its credit, the pioneering work on the development of the oral contraceptive pill and discovery of Naproxen. It had amongst its leadership team, Dr. George Rosencratz, a distinguished scientist who also received the highest honor Mexico bestows in the health field: The Eduardo Liceaga Medal.
|
|
Unit Profile |
|
Unit audited multiple times by FDA with excellent record since 1973 (32 years) |
|
Expansion potential of site |
|
398 employees |
|
125 Multi-disciplinary professionals |
|
25 post-graduates (Ph.D. and Masters) |
|
100 graduates (chemists, engineers, accountants, etc) |
|
98 technicians |
|
Installed production capacity : 3350 tons |
|
Proven technical capabilities |
|
Expertise on complex chemical syntheses |
|
Advantages due to Commercial Agreements (NAFTA, EU, etc.) |
|
|
Description of the facility
The Cuernavaca facility is USFDA inspected and consists of seven manufacturing bays. The facility is well maintained with good systems and processes, which have been developed by Roche over the last decade. Apart from manufacturing active pharmaceutical ingredients ‘naproxen & naproxen sodium’ and a range of intermediates for Roche products, this facility has pioneered the synthesis of steroids for use in pharmaceutical and veterinary industries. The key customers include Roche and other innovator companies based in North America and Europe.
|
|
|
|
| Custom Intermediates |
 |
|
|
| CPS Brochure |
 |
|
|
| Annual Report 2007 |
 |
|
| Triple Bottom Line |
 |
|
|
